Back to Search Start Over

Drug-eluting stents appear superior to bare metal stents for vein-graft PCI in vessels up to a stent diameter of 4 mm

Authors :
Oliver P. Guttmann
Daniel A. Jones
Kassem A. Safwan
Sean Gallagher
Krishnaraj S. Rathod
Steve Hamshere
Elliot J. Smith
Ajay K. Jain
Anthony Mathur
Andrew Wragg
Charles J. Knight
Roshan Weerackody
Source :
Heart International, Vol 11, Iss 1, Pp 0-0 (2016)
Publication Year :
2016
Publisher :
Touch Medical Media, 2016.

Abstract

BackgroundResearch trials have shown improved short-term outcome with drug-eluting stents (DES) over bare metal stents (BMS) in saphenous vein graft (SVG) percutaneous coronary intervention (PCI), primarily by reducing target vessel revascularization (TVR) for in-stent restenosis. We compared the outcomes in patients undergoing SVG stent implantation treated with DES or BMS. In exploratory analyses we investigated the influence of stent generation and diameter.MethodsData were obtained from a prospective database of 657 patients who underwent PCI for SVG lesions between 2003 and 2011. A total of 344 patients had PCI with BMS and 313 with DES. Propensity scores were developed based on 15 observed baseline covariates in a logistic regression model with stent type as the dependent variable. The nearest-neighbour-matching algorithm with Greedy 5-1 Digit Matching was used to produce two patient cohorts of 313 patients each. We assessed major adverse cardiac events (MACE) out to a median of 3.3 years (interquartile range: 2.1-4.1). MACE was defined as all-cause mortality, myocardial infarction (MI), TVR and stroke.ResultsThere was a significant difference in MACE between the two groups in favour of DES (17.9% DES vs. 31.2% BMS group; p = 0.0017) over the 5-year follow-up period. MACE was driven by increased TVR in the BMS group. There was no difference in death, MI or stroke. Adjusted Cox analysis confirmed a decreased risk of MACE for DES compared with BMS 0.75 (95% confidence interval (CI) 0.52-0.94), with no difference in the hazard of all-cause mortality (hazard ratio: 1.08; 95% CI: 0.77-1.68). However, when looking at stent diameters greater than 4 mm, no difference was seen in MACE rates between BMS and DES.ConclusionsOverall in our cohort of patients who had PCI for SVG disease, DES use resulted in lower MACE rates compared with BMS over a 5-year follow-up period; however, for stent diameters over 4 mm no difference in MACE rates was seen.

Details

Language :
English
ISSN :
18261868 and 20362579
Volume :
11
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Heart International
Publication Type :
Academic Journal
Accession number :
edsdoj.774c16739ecb474881572dab06827b16
Document Type :
article
Full Text :
https://doi.org/10.5301/heartint.5000228